Bharat Parenterals Reports Profit Turnaround and US Market Entry

Consolidated Revenue: INR 136.3 crore | Consolidated PAT: INR 11.8 crore

Reader Takeaway: Strong subsidiary growth and US exports drive profitability, though input cost inflation pressures standalone manufacturing margins.

What just happened

Bharat Parenterals Limited (BPL) delivered a strong financial performance in Q2 FY27, swinging to a consolidated profit of INR 11.8 crore from a loss of INR 8.6 crore in the same quarter last year. The group's consolidated revenue rose 110% YoY to INR 136.3 crore, bolstered by a 253% surge in revenue from its subsidiary, Innoxel Life Sciences, which reached INR 44.5 crore. The company board also approved a preferential issue of over 9.1 lakh shares at INR 1,522.85 per share, aiming to raise INR 139 crore for future growth.

Why this matters

The quarter marks a pivotal "commercial inflection" point for the group. The successful initiation of US commercial exports by Innoxel on October 20, 2026, signals a shift from development-heavy operations to a recurring revenue model. Simultaneously, consolidated cash from operations hit INR 83.3 crore for the first half of the year, providing the company with strong liquidity to fund its expansion plans internally.

Risks to watch

While consolidated performance is robust, the standalone business saw EBITDA margins contract to 9% from 12.3% in Q1. Management cited rising input costs triggered by geopolitical conflicts as the primary reason for this margin pressure. Additionally, Varenyam Biolifesciences remains in the pre-revenue phase, with construction ongoing until mid-2028, and Innoxel's quarterly margins may remain volatile due to the lumpy nature of licensing and milestone-based income.

What to track next

Investors should monitor how the company manages input cost inflation to stabilize standalone margins. The scaling of Innoxel's commercial manufacturing revenue remains the key growth engine to watch throughout the second half of the fiscal year.